Alpha 2.0
Login Register
» Articles » PMID: 35396319

The Role of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists in the Prevention and Treatment of Diabetic Kidney Disease: Insights from the AMPLITUDE-O Trial

Overview
Journal Clin J Am Soc Nephrol
Specialty Nephrology
Date 2022 Apr 9
PMID 35396319
Authors
Kalie L Tommerdahl
Jessica Kendrick
Petter Bjornstad
Affiliations
Soon will be listed here.
Citing Articles

Efficacy and Safety of Efpeglenatide in Patients With Type 2 Diabetes and Obesity: A Systematic Review.

Narayan N, Vadde T, Sandesara M, Divity S, Mamytova A, Tagaev T Cureus. 2025; 17(1):e77089.

PMID: 39917155 PMC: 11801804. DOI: 10.7759/cureus.77089.

GLP-1 receptor agonists' impact on cardio-renal outcomes and mortality in T2D with acute kidney disease.

Pan H, Chen J, Chen H, Yeh F, Sun C, Huang T Nat Commun. 2024; 15(1):5912.

PMID: 39003287 PMC: 11246471. DOI: 10.1038/s41467-024-50199-y.

Glucagon-like peptide-1 receptor agonists: new strategies and therapeutic targets to treat atherosclerotic cardiovascular disease.

Wang T, Ding J, Cheng X, Yang Q, Hu P Front Pharmacol. 2024; 15:1396656.

PMID: 38720777 PMC: 11076696. DOI: 10.3389/fphar.2024.1396656.

Endothelial NOX5 Obliterates the Reno-Protective Effect of Nox4 Deletion by Promoting Renal Fibrosis via Activation of EMT and ROS-Sensitive Pathways in Diabetes.

Jandeleit-Dahm K, Kankanamalage H, Dai A, Meister J, Lopez-Trevino S, Cooper M Antioxidants (Basel). 2024; 13(4).

PMID: 38671844 PMC: 11047703. DOI: 10.3390/antiox13040396.

Interplay between metabolic dysfunction-associated fatty liver disease and chronic kidney disease: Epidemiology, pathophysiologic mechanisms, and treatment considerations.

Theofilis P, Vordoni A, Kalaitzidis R World J Gastroenterol. 2022; 28(39):5691-5706.

PMID: 36338895 PMC: 9627426. DOI: 10.3748/wjg.v28.i39.5691.